Topic: chronic kidney disease
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.
Tvardi Therapeutics will finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors.
The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.
Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up an 80- to 100-person sales team.
The deal gives Novo control of orally available LPA1 receptor antagonist EPGN696 in exchange for up to $200 million in upfront and milestone payments.
Vifor Pharma and Fresenius acquired a global license to commercialize Cara Therapeutics’ Korsuva for intense itching associated with CKD and dialysis.
The new funding will advance Corvidia's lead clinical programs in chronic kidney disease and ramp up its preclinical work.
Rigel Pharma—just days away from hearing from the FDA on its first marketing application for lead drug fostamatinib—has reported disappointing phase 2 data in a follow-up indication.
Osprey Medical has raised $17.5 million for its device that makes a heart procedure safer for patients with chronic kidney disease.